Product introduction

  Agomelatine was first launched in Europe in 2009 and is now approved for use in more than 70 countries. Unlike traditional antidepressants, agomelatine works by targeting melatonin and serotonin receptors in the brain. By acting as an agonist at melatonin receptors, agomelatine helps normalize the disrupted sleep patterns often associated with depression. This mechanism not only helps improve sleep quality but also helps restore natural circadian rhythms. In addition, agomelatine acts as an antagonist at certain serotonin receptors ( 5-HT2C receptors). This unique dual action indirectly enhances the availability of serotonin in the brain, a neurotransmitter responsible for regulating mood. By regulating serotonin levels, agomelatine can act as an effective antidepressant, relieving symptoms such as sadness, loss of interest, feelings of guilt or worthlessness. Additionally, agomelatine may provide other benefits. Research suggests it may help improve cognitive function Research demonstrates its potential to enhance memory, attention, and executive function, making it an exciting area for future research.

 Feature

  (1) High purity: Agomelatine can obtain high-purity products through natural extraction and refining production processes. High purity means better bioavailability and fewer adverse reactions.
 (2) Safety: High safety, few adverse reactions, and the scope of impact is also very small.
 (3) Stability: Agomelatine has good stability and can maintain its activity and effect under different environments and storage conditions.
 (4) Easy to absorb: Agomelatine can be quickly absorbed by the body.

 Applications

Agomelatine is an antidepressant and a melatonin antagonist. It reduces depressive symptoms by regulating melatonin MT1 receptors (reduces cortical alarm signals) and MT2 receptors (circadian sleep rhythm) and serotonin levels. Taken at night, it mimics the natural rhythm of melatonin release and can significantly improve sleep quality. Its mechanism of action breaks through the traditional monoamine transmitter system. It activates melatonin receptors MT1 and MT2 and antagonizes 5-HT2C receptors. Improves sleep quality, restores biological rhythm, and has an antidepressant effect; among them, by antagonizing 5-HT2C receptors on the postsynaptic membrane, it can increase the release of DA and NE in the prefrontal cortex, exerting an antidepressant effect. When MT agonism and 5-HT2C receptor antagonism coexist, a unique synergistic effect can be produced, promoting the release of more DA and NE in the PFC brain area, further strengthening the antidepressant effect. In addition, agomelatine can promote the release of brain-derived neurotrophic factor in the PFC and block the stress-induced release of glutamate in the amygdala brain area.